Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

MLA

Fornecker, Luc-Matthieu, et al. “Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.” Journal of Clinical Oncology, vol. 41, no. 2, Jan. 2023, pp. 327–35. EBSCOhost, https://doi.org/10.1200/JCO.21.01281.

APA

Fornecker, L.-M., Lazarovici, J., Aurer, I., Casasnovas, R.-O., Gac, A.-C., Bonnet, C., Bouabdallah, K., Feugier, P., Specht, L., Molina, L., Touati, M., Borel, C., Stamatoullas, A., Nicolas-Virelizier, E., Pascal, L., Lugtenburg, P., Di Renzo, N., Vander Borght, T., Traverse-Glehen, A., & Dartigues, P. (2023). Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of Clinical Oncology, 41(2), 327–335. https://doi.org/10.1200/JCO.21.01281

Chicago

Fornecker, Luc-Matthieu, Julien Lazarovici, Igor Aurer, René-Olivier Casasnovas, Anne-Claire Gac, Christophe Bonnet, Krimo Bouabdallah, et al. 2023. “Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.” Journal of Clinical Oncology 41 (2): 327–35. doi:10.1200/JCO.21.01281.